喜炎平注射液治疗儿童呼吸系统疾病的快速卫生技术评估

A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children

目的:快速评估喜炎平注射液治疗儿童呼吸系统疾病的有效性、安全性和经济性,为临床合理用药提供循证证据。方法:通过对万方数据库、中国知网、中国生物医学文献数据库、Embase、the Cochrane Library和PubMed等网站进行检索,纳入喜炎平注射液治疗儿童呼吸系统疾病的卫生技术评估(HTA)报告、系统评价/Meta分析和药物经济学研究,对纳入的资料进行分析汇总,并对文献及其方法学进行质量评价。结果:共纳入20篇文献,其中15篇为系统评价/Meta分析,5篇为药物经济学研究,未检索到HTA报告。分析结果显示,喜炎平注射液单独或联合西药治疗儿童呼吸系统疾病,在提高总有效率,缩短退热时间,缩短咳嗽、肺部啰音、气促、憋喘、咽痛和鼻塞流涕等临床症状缓解或消失时间,加快炎症吸收(胸部X线检查),降低血清炎症因子水平,缩短住院时间和提高治愈率等方面均有一定作用。同时,喜炎平注射液的不良反应发生率显著低于对照组或与对照组相近。结论:喜炎平注射液治疗儿童呼吸系统疾病,可有效改善相关临床症状。未来可针对该药开展更深入的药物经济学研究和更为规范的临床观察、安全性评价,补充相关用药循证证据。

OBJECTIVE: To rapidly evaluate the efficacy, safety and economical efficiency of Xiyanping injection in the treatment of respiratory system diseases in children, so as to provide evidence-based evidence for clinical rational drug use. METHODS: Wanfang Data, CNKI, CBM, Embase, the Cochrane Library and PubMed were retrieved to collect the health technology assessment(HTA) reports, systematic reviews/Meta-analysis and pharmacoeconomic studies related to Xiyangping injection in the treatment of respiratory system diseases in children. The included data were analyzed and summarized, and quality evaluation was performed on the literature and its methodology. RESULTS: A total of 20 articles were enrolled, 15 were systematic reviews/Meta-analysis, 5 were pharmacoeconomic studies, and no HTA reports were retrieved. Xiyanping injection alone or in combination with western medicine in the treatment of respiratory system diseases in children can improve the total effective rate, shorten the duration of fever, shorten the relief or disappearance time of cough, lung rales, shortness of breath, dyspnea, sore throat, nasal congestion and runny nose, accelerate the absorption of inflammation(chest X-ray examination), reduce the serum inflammatory factor levels, shorten the length of stay, and improve the cure rate. Meanwhile, the incidence of adverse drug reactions of Xiyanping injection was significantly lower than or similar to the control group. CONCLUSIONS: Xiyanping jing injection has favorable efficacy in the treatment of respiratory system diseases in children. In the future, more in-depth pharmacoeconomic research and standardized clinical observations and safety evaluations can be carried out for Xiyanping injection, so as to provide the evidence-based evidence of related drug use.